Current use and acceptability of novel diagnostic tests for active tuberculosis: A worldwide survey

TB Diagnostic Survey Working Group

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To determine the current use and potential acceptance (by tuberculosis experts worldwide) of novel rapid tests for the diagnosis of tuberculosis that are in line with World Health Organization target product profiles. Methods: A multilingual survey was disseminated online between July and November of 2016. Results: A total of 723 individuals from 114 countries responded to the survey. Smear microscopy was the most commonly used rapid tuberculosis test (available to 90.9% of the respondents), followed by molecular assays (available to 70.7%). Only a small proportion of the respondents in middle- and low-income countries had access to interferon-gamma-release assays. Serological and lateral flow immunoassays were used by more than a quarter (25.4%) of the respondents. Among the respondents who had access to molecular tests, 46.7% were using the Xpert assay overall, that proportion being higher in lower middle-income countries (55.6%) and low-income countries (76.6%). The data also suggest that there was some alignment of pricing for molecular assays. Respondents stated they would accept novel rapid tuberculosis tests if available, including molecular assays (acceptable to 86.0%) or biomarker-based serological assays (acceptable to 81.7%). Simple biomarker-based assays were more commonly deemed acceptable in middle- and low-income countries. Conclusions: Second-generation molecular assays have become more widely available in high- and low-resource settings. However, the development of novel rapid tuberculosis tests continues to be considered important by tuberculosis experts. Our data also underscore the need for additional training and education of end users. © 2017 Sociedade Brasileira de Pneumologia e Tisiologia.
Original languageEnglish
Pages (from-to)380-392
Number of pages13
JournalJornal Brasileiro de Pneumologia
Volume43
Issue number5
DOIs
Publication statusPublished - 2017

Fingerprint

Routine Diagnostic Tests
Tuberculosis
Biomarkers
Interferon-gamma Release Tests
Surveys and Questionnaires
Immunoassay
Microscopy
Education
Costs and Cost Analysis

Cite this

Current use and acceptability of novel diagnostic tests for active tuberculosis: A worldwide survey. / TB Diagnostic Survey Working Group.

In: Jornal Brasileiro de Pneumologia, Vol. 43, No. 5, 2017, p. 380-392.

Research output: Contribution to journalArticle

@article{d31cecb83d99421ca912dc21a4ceb3aa,
title = "Current use and acceptability of novel diagnostic tests for active tuberculosis: A worldwide survey",
abstract = "Objective: To determine the current use and potential acceptance (by tuberculosis experts worldwide) of novel rapid tests for the diagnosis of tuberculosis that are in line with World Health Organization target product profiles. Methods: A multilingual survey was disseminated online between July and November of 2016. Results: A total of 723 individuals from 114 countries responded to the survey. Smear microscopy was the most commonly used rapid tuberculosis test (available to 90.9{\%} of the respondents), followed by molecular assays (available to 70.7{\%}). Only a small proportion of the respondents in middle- and low-income countries had access to interferon-gamma-release assays. Serological and lateral flow immunoassays were used by more than a quarter (25.4{\%}) of the respondents. Among the respondents who had access to molecular tests, 46.7{\%} were using the Xpert assay overall, that proportion being higher in lower middle-income countries (55.6{\%}) and low-income countries (76.6{\%}). The data also suggest that there was some alignment of pricing for molecular assays. Respondents stated they would accept novel rapid tuberculosis tests if available, including molecular assays (acceptable to 86.0{\%}) or biomarker-based serological assays (acceptable to 81.7{\%}). Simple biomarker-based assays were more commonly deemed acceptable in middle- and low-income countries. Conclusions: Second-generation molecular assays have become more widely available in high- and low-resource settings. However, the development of novel rapid tuberculosis tests continues to be considered important by tuberculosis experts. Our data also underscore the need for additional training and education of end users. {\circledC} 2017 Sociedade Brasileira de Pneumologia e Tisiologia.",
author = "M Amicosante and L D’Ambrosio and Marcela Munoz and FCdQ Mello and M Tebruegge and NN Chegou and F Seghrouchni and R Centis and D Goletti and G Bothamley and GB Migliori and {TB Diagnostic Survey Working Group}",
note = "Cirillo, DM in appendice",
year = "2017",
doi = "10.1590/s1806-37562017000000219",
language = "English",
volume = "43",
pages = "380--392",
journal = "Jornal Brasileiro de Pneumologia",
issn = "1806-3713",
publisher = "Sociedade Brasileira de Pneumologia e Tisiologia",
number = "5",

}

TY - JOUR

T1 - Current use and acceptability of novel diagnostic tests for active tuberculosis: A worldwide survey

AU - Amicosante, M

AU - D’Ambrosio, L

AU - Munoz, Marcela

AU - Mello, FCdQ

AU - Tebruegge, M

AU - Chegou, NN

AU - Seghrouchni, F

AU - Centis, R

AU - Goletti, D

AU - Bothamley, G

AU - Migliori, GB

AU - TB Diagnostic Survey Working Group

N1 - Cirillo, DM in appendice

PY - 2017

Y1 - 2017

N2 - Objective: To determine the current use and potential acceptance (by tuberculosis experts worldwide) of novel rapid tests for the diagnosis of tuberculosis that are in line with World Health Organization target product profiles. Methods: A multilingual survey was disseminated online between July and November of 2016. Results: A total of 723 individuals from 114 countries responded to the survey. Smear microscopy was the most commonly used rapid tuberculosis test (available to 90.9% of the respondents), followed by molecular assays (available to 70.7%). Only a small proportion of the respondents in middle- and low-income countries had access to interferon-gamma-release assays. Serological and lateral flow immunoassays were used by more than a quarter (25.4%) of the respondents. Among the respondents who had access to molecular tests, 46.7% were using the Xpert assay overall, that proportion being higher in lower middle-income countries (55.6%) and low-income countries (76.6%). The data also suggest that there was some alignment of pricing for molecular assays. Respondents stated they would accept novel rapid tuberculosis tests if available, including molecular assays (acceptable to 86.0%) or biomarker-based serological assays (acceptable to 81.7%). Simple biomarker-based assays were more commonly deemed acceptable in middle- and low-income countries. Conclusions: Second-generation molecular assays have become more widely available in high- and low-resource settings. However, the development of novel rapid tuberculosis tests continues to be considered important by tuberculosis experts. Our data also underscore the need for additional training and education of end users. © 2017 Sociedade Brasileira de Pneumologia e Tisiologia.

AB - Objective: To determine the current use and potential acceptance (by tuberculosis experts worldwide) of novel rapid tests for the diagnosis of tuberculosis that are in line with World Health Organization target product profiles. Methods: A multilingual survey was disseminated online between July and November of 2016. Results: A total of 723 individuals from 114 countries responded to the survey. Smear microscopy was the most commonly used rapid tuberculosis test (available to 90.9% of the respondents), followed by molecular assays (available to 70.7%). Only a small proportion of the respondents in middle- and low-income countries had access to interferon-gamma-release assays. Serological and lateral flow immunoassays were used by more than a quarter (25.4%) of the respondents. Among the respondents who had access to molecular tests, 46.7% were using the Xpert assay overall, that proportion being higher in lower middle-income countries (55.6%) and low-income countries (76.6%). The data also suggest that there was some alignment of pricing for molecular assays. Respondents stated they would accept novel rapid tuberculosis tests if available, including molecular assays (acceptable to 86.0%) or biomarker-based serological assays (acceptable to 81.7%). Simple biomarker-based assays were more commonly deemed acceptable in middle- and low-income countries. Conclusions: Second-generation molecular assays have become more widely available in high- and low-resource settings. However, the development of novel rapid tuberculosis tests continues to be considered important by tuberculosis experts. Our data also underscore the need for additional training and education of end users. © 2017 Sociedade Brasileira de Pneumologia e Tisiologia.

U2 - 10.1590/s1806-37562017000000219

DO - 10.1590/s1806-37562017000000219

M3 - Article

VL - 43

SP - 380

EP - 392

JO - Jornal Brasileiro de Pneumologia

JF - Jornal Brasileiro de Pneumologia

SN - 1806-3713

IS - 5

ER -